The genotype-phenotype association of CYP3A4 and CYP3A5 polymorphisms to midazolam clearance in vivo

被引：0
|
作者：
He, P [1 ]
Court, MH [1 ]
Greenblatt, DJ [1 ]
von Moltke, LL [1 ]
机构：
[1] Tufts Univ, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2004年 / 44卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
103
引用
收藏
页码：1209 / 1209
页数：1
相关论文
共 50 条
  • [41] Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina
    Semiz, Sabina
    Dujic, Tanja
    Ostanek, Barbara
    Prnjavorac, Besim
    Bego, Tamer
    Malenica, Maja
    Mlinar, Barbara
    Marc, Janja
    Causevic, Adlija
    MEDICINSKI GLASNIK, 2011, 8 (01) : 84 - 89
  • [42] Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5*3 genotype in Chinese renal transplant recipients
    Luo, Xi
    Zhu, Li-jun
    Cai, Ning-fang
    Zheng, Li-yun
    Cheng, Ze-neng
    ACTA PHARMACOLOGICA SINICA, 2016, 37 (04) : 555 - 560
  • [43] Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: A possible role of intestinal CYP3A4 expression
    Ufer, M.
    Dilger, K.
    Leschhorn, L.
    Daufresne, L. M.
    Mosyagin, I.
    Rosenstiel, P.
    Haesler, R.
    Kuehbacher, T.
    Nikolaus, S.
    Schreiber, S.
    Cascorbi, I.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (01) : 43 - 46
  • [44] Tacrolimus Elimination in Four Patients With a CYP3A5*3/*3 CYP3A4*22/*22 Genotype Combination
    Scheibner, Aileen
    Remmel, Rory
    Schladt, David
    Oetting, William S.
    Guan, Weihua
    Wu, Baolin
    Dorr, Casey
    Israni, Ajay
    Jacobson, Pamala A.
    PHARMACOTHERAPY, 2018, 38 (07): : E46 - E52
  • [45] Association between the CYP3A4 and CYP3A5 polymorphisms and cancer risk: a meta-analysis and meta-regression
    He, Xiao-Feng
    Liu, Zhi-Zhong
    Xie, Jian-Jun
    Wang, Wei
    Du, Ya-Ping
    Chen, Yu
    Wei, Wu
    TUMOR BIOLOGY, 2014, 35 (10) : 9859 - 9877
  • [46] Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant
    Hannachi, Ibtissem
    Ben Fredj, Nadia
    Chadli, Zohra
    Ben Fadhel, Najah
    Ben Romdhane, Haifa
    Touitou, Yvan
    Boughattas, Naceur A.
    Chaabane, Amel
    Aouam, Karim
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2020, 396
  • [47] USE OF THE CYP3A4 SELECTIVE INHIBITOR CYP3CIDE IN CYP3A5 GENOTYPED CRYOPRESERVED HUMAN HEPATOCYTES TO EXPLORE THE INDIVIDUAL CONTRIBUTION OF CYP3A4 AND CYP3A5 IN DRUG METABOLISM
    Heyward, Scott
    Schultz, Rachel N. V.
    Dennell, Stephen
    DRUG METABOLISM REVIEWS, 2014, 45 : 135 - 136
  • [48] Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study
    Hamaoka, N
    Oda, Y
    Hase, I
    Mizutani, K
    Nakamoto, T
    Ishizaki, T
    Asada, A
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (02) : 110 - 117
  • [49] Propofol decreases the clearance of midazolam by inhibiting CYP3A4: In vivo and in vitro study
    Hamaoka, N
    Oda, Y
    Hase, I
    Asada, A
    ANESTHESIOLOGY, 1999, 91 (3A) : U244 - U244
  • [50] Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue
    Kivisto, KT
    Bookjans, G
    Fromm, MF
    Griese, EU
    Munzel, P
    Kroemer, HK
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (03) : 387 - 389
12345